Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. Stock

Equities

301093

CNE100004YH2

Tires & Rubber Products

End-of-day quote Shenzhen S.E. 18:00:00 2024-04-25 EDT 5-day change 1st Jan Change
22.28 CNY -8.16% Intraday chart for Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. -8.58% -31.02%

Financials

Sales 2024 * 1.11B 153M 209M Sales 2025 * 1.57B 217M 296M Capitalization 2.88B 397M 543M
Net income 2024 * 182M 25.12M 34.34M Net income 2025 * 283M 39.06M 53.4M EV / Sales 2024 * 2.6 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 1.83 x
P/E ratio 2024 *
16.5 x
P/E ratio 2025 *
10.6 x
Employees 877
Yield 2024 *
-
Yield 2025 *
-
Free-Float 63.14%
More Fundamentals * Assessed data
Dynamic Chart
Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on Jiangsu Hualan New Pharmaceutical Material Co.,Ltd.'s Equity Buyback Plan announced on June 6, 2023. CI
Jiangsu Hualan New Pharmaceutical Material Co.,Ltd.'s Equity Buyback announced on June 6, 2023 has closed with 6,412,625 shares, representing 4.81% for CNY 199.59 million. CI
Tranche Update on Jiangsu Hualan New Pharmaceutical Material Co.,Ltd.'s Equity Buyback Plan announced on June 6, 2023. CI
Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Tranche Update on Jiangsu Hualan New Pharmaceutical Material Co.,Ltd.'s Equity Buyback Plan announced on June 6, 2023. CI
Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on May 26, 2023. CI
Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Jiangsu Hualan New Pharmaceutical Material Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Jiangsu Hualan New Pharmaceutical Material Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Chongqing Fuling Sanhai Lanling Co., Ltd. announced that it expects to receive CNY 576.3965 million in funding from Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. CI
Jiangsu Hualan New Pharma to List 1.8 Million Shares Post IPO Lock-Up Period MT
More news
1 day-8.16%
1 week-8.58%
Current month-12.97%
1 month-10.52%
3 months-22.75%
6 months-35.46%
Current year-31.02%
More quotes
1 week
21.79
Extreme 21.79
24.75
1 month
21.79
Extreme 21.79
26.10
Current year
21.50
Extreme 21.5
32.54
1 year
21.50
Extreme 21.5
36.59
3 years
21.50
Extreme 21.5
57.88
5 years
21.50
Extreme 21.5
57.88
10 years
21.50
Extreme 21.5
57.88
More quotes
Managers TitleAgeSince
Chief Executive Officer 42 08-12-31
Director of Finance/CFO 51 19-05-31
Director/Board Member 61 97-12-31
Members of the board TitleAgeSince
Director/Board Member 53 22-03-21
Director/Board Member 55 97-12-31
Director/Board Member 45 22-03-21
More insiders
Date Price Change Volume
24-04-26 22.28 -8.16% 7,886,548
24-04-25 24.26 -0.41% 1,180,937
24-04-24 24.36 +1.00% 789,600
24-04-23 24.12 -1.11% 1,124,063
24-04-22 24.39 +0.08% 1,165,658

End-of-day quote Shenzhen S.E., April 25, 2024

More quotes
Jiangsu Hualan New Pharmaceutical Material Co Ltd is a China-based company primarily engaged in the research, development, production and sales of packaging materials for direct contact injection drugs. The Company’s main products include various kinds of coated rubber stoppers, conventional rubber stoppers and others. The Company's products are mainly used in the field of pharmaceutical preparations such as infusion, freeze-drying, powder injection, monoclonal antibodies, small water injections, blood sampling, and Chinese medicine compound preparations, among others. The Company also produces plastic infusion container assemblies and urinary anorectal minimally invasive surgical instruments. The Company distributes its products within the domestic market and to overseas markets, including Italy, Egypt, Saudi Arabia, Qatar and other areas.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
22.28 CNY
Average target price
43.78 CNY
Spread / Average Target
+96.50%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 301093 Stock